Paul G. Richardson, MD, on a New Triplet Therapy in Relapsed/Refractory Multiple Myeloma

Posted: Sunday, June 2, 2019

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses isatuximab, pomalidomide, and dexamethasone as a new treatment option for relapsed/refractory multiple myeloma in light of phase III trial findings comparing the triplet with pomalidomide and dexamethasone.